In-Depth Focus From CHEST 2019: COPD

How Do Seasonal Variants Affect Outcomes, Costs in COPD?

By

Madeline Morr

Publish Date October 30, 2019

Researchers conducted a retrospective analysis to identify seasonal variations in outcomes for COPD exacerbation admissions and the effect on healthcare resource utilization.

Aclidinium Bromide Safe, Reduces Exacerbations in COPD With CV Risk

By

Britt Gambino

Publish Date October 30, 2019

Treatment with aclidinium bromide reduced the rate of exacerbations in patients with moderate to severe COPD and high cardiovascular risk.

Rates and Predictors of Hospital Readmission for COPD Exacerbation

By

Pulmonology Advisor Contributing Writer

Publish Date October 30, 2019

One in 20 patients admitted to the hospital for an exacerbation of COPD was readmitted within 30 days.

Safety Profile of Revefenacin Administered With Formoterol in COPD

By

Pulmonology Advisor Contributing Writer

Publish Date October 30, 2019

In patients with COPD, revefenacin demonstrated a safety profile similar to that of formoterol alone when given either before or combined with formoterol through a standard jet nebulizer.

Depression Linked to Increased Clinical Burden, Hospitalization Risk in COPD

By

Benjamin Williams

Publish Date October 30, 2019

Depression is linked to increased clinical burden in patients with COPD.

Predictors of Suboptimal Peak Inspiratory Flow Rate in COPD

By

Pulmonology Advisor Contributing Writer

Publish Date October 30, 2019

Patients with COPD who have suboptimal peak inspiratory flow rate tend to have longer disease duration, be more symptomatic, have more severe airflow obstruction, and lower lung function, weight, and BMI.